Takeda targets 2027 India launch for Qdenga dengue vaccine
Takeda plans to commercially launch its DCGI-approved Qdenga dengue vaccine in India in the first half of 2027, beginning with private channels before pursuing state and central procurement. The two-dose vaccine is approved for people aged 4-60.
Takeda plans to commercially launch its DCGI-approved Qdenga dengue vaccine in India in the first half of 2027, initially through private channels. It will pursue state and central procurement and eventual inclusion in the National Immunisation Programme.
Why this matters
No related recent Takeda signals are provided; the planned Qdenga launch marks a prospective India market-entry step for the company’s dengue vaccine.
Retail-company signals are accelerating, up 204914% QoQ.